Health and Aging Brain Study–Health Disparities (HABS-HD) methods and partner characteristics

IF 6.8 Q1 CLINICAL NEUROLOGY

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Pub Date : 2025-08-12 DOI:10.1002/trc2.70140

Melissa E. Petersen, Zhengyang Zhou, James R. Hall, Nicole Phillips, Karin L. Meeker, Matthew T. Borzage, Meredith N. Braskie, Alexandra L. Clark, Yonggang Shi, Robert A. Rissman, Fan Zhang, Raul Vintimilla, Antonio Casas, Jill Rhodes, Robert C. Barber, Leigh Johnson, Kristine Yaffe, Arthur W. Toga, Sid E. O'Bryant, for the HABS-HD Study Team

{"title":"Health and Aging Brain Study–Health Disparities (HABS-HD) methods and partner characteristics","authors":"Melissa E. Petersen, Zhengyang Zhou, James R. Hall, Nicole Phillips, Karin L. Meeker, Matthew T. Borzage, Meredith N. Braskie, Alexandra L. Clark, Yonggang Shi, Robert A. Rissman, Fan Zhang, Raul Vintimilla, Antonio Casas, Jill Rhodes, Robert C. Barber, Leigh Johnson, Kristine Yaffe, Arthur W. Toga, Sid E. O'Bryant, for the HABS-HD Study Team","doi":"10.1002/trc2.70140","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> INTRODUCTION</h3>\n \n <p>The Health and Aging Brain Study–Health Disparities (HABS-HD) is an ongoing prospective study aimed at understanding brain health and aging. The current work provides a description of the cohort baseline characteristics and outlines the study methodology.</p>\n </section>\n \n <section>\n \n <h3> METHODS</h3>\n \n <p>We analyzed available data from <i>n</i> = 1066 non-Hispanic Black (NHB), <i>n</i> = 1425 Hispanic, and <i>n</i> = 1349 non-Hispanic White (NHW) partners who were actively enrolled in HABS-HD. Descriptive statistics are presented for each racial/ethnic group across demographic, medical, and diagnostic characteristics. Differences in select amyloid (A), tau (T), and neurodegenerative (N) biomarkers spanning proteomic and neuroimaging were examined along with groupwise differences for cognitive test performance and select social determinants of health (SDoH) factors.</p>\n </section>\n \n <section>\n \n <h3> RESULTS</h3>\n \n <p>The characteristics of the cohort revealed significant groupwise differences in age, education, sex, and cognitive diagnosis. Higher rates of cognitive impairment (mild cognitive impairment [MCI] and dementia) were found in NHB and Hispanic compared to NHW partners, despite the latter group being older. There were also higher rates of hypertension and diabetes among NHB and Hispanic compared to NHW partners. Differences were also found across many plasma (A/T[N]) biomarkers and select neuroimaging measures, including meta-region of interest and white matter hyperintensities. Positron emission tomography amyloid positivity rates (but not tau positivity) were found to differ, with higher rates observed among NHW (15% amyloid positivity) compared to NHB (3%) partners. Groups also differed by select SDoH factors, including household income, insurance, having a health-care provider, and Area Deprivation Index. All cognitive measures also revealed groupwise differences.</p>\n </section>\n \n <section>\n \n <h3> DISCUSSION</h3>\n \n <p>The baseline cohort characteristics for HABS-HD reveal significant group differences spanning demographic, medical, cognitive, and biological factors (including A/T[N] biomarkers), which are all critical to understand as they relate to aging and age-related diseases.</p>\n </section>\n \n <section>\n \n <h3> Highlights</h3>\n \n <div>\n <ul>\n \n <li>The Health and Aging Brain Study–Health Disparities (HABS-HD) cohort baseline characteristics and study methodology were provided.</li>\n \n <li>Cohort characteristic differences were found across demographic factors, including age, education, sex, and cognitive diagnosis across the representative groups.</li>\n \n <li>Biomarkers for amyloid/tau/neurodegeneration spanning blood and neuroimaging were shown to differ as well across cohort groups.</li>\n \n <li>Positivity rates for amyloid positron emission tomography were lower for non-Hispanic Black partners in the cohort compared to non-Hispanic White partners.</li>\n </ul>\n </div>\n </section>\n </div>","PeriodicalId":53225,"journal":{"name":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","volume":"11 3","pages":""},"PeriodicalIF":6.8000,"publicationDate":"2025-08-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://alz-journals.onlinelibrary.wiley.com/doi/epdf/10.1002/trc2.70140","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Alzheimer''s and Dementia: Translational Research and Clinical Interventions","FirstCategoryId":"1085","ListUrlMain":"https://alz-journals.onlinelibrary.wiley.com/doi/10.1002/trc2.70140","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

INTRODUCTION

The Health and Aging Brain Study–Health Disparities (HABS-HD) is an ongoing prospective study aimed at understanding brain health and aging. The current work provides a description of the cohort baseline characteristics and outlines the study methodology.

METHODS

We analyzed available data from n = 1066 non-Hispanic Black (NHB), n = 1425 Hispanic, and n = 1349 non-Hispanic White (NHW) partners who were actively enrolled in HABS-HD. Descriptive statistics are presented for each racial/ethnic group across demographic, medical, and diagnostic characteristics. Differences in select amyloid (A), tau (T), and neurodegenerative (N) biomarkers spanning proteomic and neuroimaging were examined along with groupwise differences for cognitive test performance and select social determinants of health (SDoH) factors.

RESULTS

The characteristics of the cohort revealed significant groupwise differences in age, education, sex, and cognitive diagnosis. Higher rates of cognitive impairment (mild cognitive impairment [MCI] and dementia) were found in NHB and Hispanic compared to NHW partners, despite the latter group being older. There were also higher rates of hypertension and diabetes among NHB and Hispanic compared to NHW partners. Differences were also found across many plasma (A/T[N]) biomarkers and select neuroimaging measures, including meta-region of interest and white matter hyperintensities. Positron emission tomography amyloid positivity rates (but not tau positivity) were found to differ, with higher rates observed among NHW (15% amyloid positivity) compared to NHB (3%) partners. Groups also differed by select SDoH factors, including household income, insurance, having a health-care provider, and Area Deprivation Index. All cognitive measures also revealed groupwise differences.

DISCUSSION

The baseline cohort characteristics for HABS-HD reveal significant group differences spanning demographic, medical, cognitive, and biological factors (including A/T[N] biomarkers), which are all critical to understand as they relate to aging and age-related diseases.

Highlights

The Health and Aging Brain Study–Health Disparities (HABS-HD) cohort baseline characteristics and study methodology were provided.
Cohort characteristic differences were found across demographic factors, including age, education, sex, and cognitive diagnosis across the representative groups.
Biomarkers for amyloid/tau/neurodegeneration spanning blood and neuroimaging were shown to differ as well across cohort groups.
Positivity rates for amyloid positron emission tomography were lower for non-Hispanic Black partners in the cohort compared to non-Hispanic White partners.

Abstract Image

查看原文本刊更多论文

健康与衰老脑研究-健康差异（HABS-HD）方法和伴侣特征

健康与衰老脑研究-健康差异（HABS-HD）是一项正在进行的前瞻性研究，旨在了解大脑健康和衰老。目前的工作提供了队列基线特征的描述，并概述了研究方法。方法：我们分析了n = 1066名非西班牙裔黑人（NHB）、n = 1425名西班牙裔和n = 1349名积极参加HABS-HD的非西班牙裔白人（NHW）伴侣的现有数据。描述统计资料介绍了每个种族/族裔群体的人口统计、医学和诊断特征。选择淀粉样蛋白(A), tau (T)和神经退行性(N)生物标志物跨越蛋白质组学和神经影像学的差异，以及认知测试表现和选择健康社会决定因素（SDoH）因素的组间差异进行了检查。结果该队列的特征在年龄、教育程度、性别和认知诊断方面显示出显著的组间差异。与NHW伴侣相比，NHB和西班牙裔伴侣的认知障碍（轻度认知障碍[MCI]和痴呆）发生率更高，尽管后者年龄较大。与NHW合作伙伴相比，NHB和西班牙裔的高血压和糖尿病发病率也更高。在许多血浆（A/T[N]）生物标志物和选择的神经成像测量中也发现了差异，包括兴趣元区和白质高信号。正电子发射断层扫描发现淀粉样蛋白阳性率（但不是tau阳性）存在差异，NHW的淀粉样蛋白阳性率（15%）高于NHB（3%）。各组在特定的SDoH因素方面也存在差异，包括家庭收入、保险、是否有保健提供者和地区贫困指数。所有的认知测试也揭示了群体间的差异。HABS-HD的基线队列特征揭示了人口统计学、医学、认知和生物学因素（包括A/T[N]生物标志物）方面的显著组间差异，这些因素对于理解与衰老和年龄相关疾病相关的因素都至关重要。提供了健康与衰老脑研究-健康差异（HABS-HD）队列基线特征和研究方法。在人口统计学因素中发现了队列特征差异，包括代表性群体的年龄、教育程度、性别和认知诊断。淀粉样蛋白/tau/神经变性的生物标志物跨越血液和神经影像学显示在队列组之间也存在差异。与非西班牙裔白人伴侣相比，非西班牙裔黑人伴侣的淀粉样蛋白正电子发射断层扫描阳性率较低。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Alzheimer''s and Dementia: Translational Research and Clinical Interventions Medicine-Psychiatry and Mental Health

CiteScore

10.10

自引率

2.10%

发文量

134

审稿时长

10 weeks

期刊介绍： Alzheimer''s & Dementia: Translational Research & Clinical Interventions (TRCI) is a peer-reviewed, open access,journal from the Alzheimer''s Association®. The journal seeks to bridge the full scope of explorations between basic research on drug discovery and clinical studies, validating putative therapies for aging-related chronic brain conditions that affect cognition, motor functions, and other behavioral or clinical symptoms associated with all forms dementia and Alzheimer''s disease. The journal will publish findings from diverse domains of research and disciplines to accelerate the conversion of abstract facts into practical knowledge: specifically, to translate what is learned at the bench into bedside applications. The journal seeks to publish articles that go beyond a singular emphasis on either basic drug discovery research or clinical research. Rather, an important theme of articles will be the linkages between and among the various discrete steps in the complex continuum of therapy development. For rapid communication among a multidisciplinary research audience involving the range of therapeutic interventions, TRCI will consider only original contributions that include feature length research articles, systematic reviews, meta-analyses, brief reports, narrative reviews, commentaries, letters, perspectives, and research news that would advance wide range of interventions to ameliorate symptoms or alter the progression of chronic neurocognitive disorders such as dementia and Alzheimer''s disease. The journal will publish on topics related to medicine, geriatrics, neuroscience, neurophysiology, neurology, psychiatry, clinical psychology, bioinformatics, pharmaco-genetics, regulatory issues, health economics, pharmacoeconomics, and public health policy as these apply to preclinical and clinical research on therapeutics.